Insmed reported $132.07M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Cytokinetics USD 0 0 Dec/2023
Gilead Sciences USD 1.78B 40M Sep/2025
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Insmed USD 132.07M 11.1M Dec/2025
Novartis USD 6.42B 114M Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vertex Pharmaceuticals USD 1.69B 60M Dec/2025